Cargando…
Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
BACKGROUND: During the last decade, oral bisphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk su...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141385/ https://www.ncbi.nlm.nih.gov/pubmed/21702989 http://dx.doi.org/10.1186/1472-6963-11-151 |